KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Research & Development (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Research & Development readings, the most recent being $364.9 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 37.62% to $364.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 billion, a 25.58% increase, with the full-year FY2025 number at $1.3 billion, up 17.19% from a year prior.
  • Research & Development hit $364.9 million in Q1 2026 for Alnylam Pharmaceuticals, down from $372.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $372.2 million in Q4 2025 to a low of $169.9 million in Q1 2022.
  • Median Research & Development over the past 5 years was $265.1 million (2025), compared with a mean of $276.4 million.
  • Biggest five-year swings in Research & Development: fell 8.61% in 2022 and later skyrocketed 37.62% in 2026.
  • Alnylam Pharmaceuticals' Research & Development stood at $262.0 million in 2022, then rose by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 24.0% to $372.2 million in 2025, then dropped by 1.98% to $364.9 million in 2026.
  • The last three reported values for Research & Development were $364.9 million (Q1 2026), $372.2 million (Q4 2025), and $358.8 million (Q3 2025) per Business Quant data.